Matt Kelley

Matt Kelley is a Senior Scientist at Alexion Pharmaceuticals, Inc., specializing in preclinical rare disease gene therapies since September 2023. Prior to this role, Matt served as a Senior Scientist in the Rare Disease Research Unit at Pfizer from July 2021 to September 2023, where responsibilities included leading preclinical AAV gene therapy and small molecule programs for rare neurology and engaging in strategic discussions with key opinion leaders. Matt's earlier experience includes serving as a Scientist I at Voyager Therapeutics, focusing on AAV gene therapy for chronic pain, and working as a Postdoctoral Fellow at Amgen, investigating the neurophysiological mechanisms of the migraine treatment Aimovig. Matt earned a PhD in Neuroscience from Tufts University and a BS in Neuroscience from UCLA.